KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organon (OGN) EBT (2020 - 2026)

Organon has reported EBT over the past 7 years, most recently at $213.0 million for Q1 2026.

  • For Q1 2026, EBT rose 110.89% year-over-year to $213.0 million; the TTM value through Mar 2026 reached $537.0 million, down 20.09%, while the annual FY2025 figure was $425.0 million, 47.34% down from the prior year.
  • EBT for Q1 2026 was $213.0 million at Organon, up from -$148.0 million in the prior quarter.
  • Over five years, EBT peaked at $562.0 million in Q4 2022 and troughed at -$148.0 million in Q4 2025.
  • A 5-year average of $217.1 million and a median of $235.0 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: skyrocketed 158.75% in 2024 and later plummeted 214.73% in 2025.
  • Year by year, EBT stood at $562.0 million in 2022, then tumbled by 81.49% to $104.0 million in 2023, then grew by 24.04% to $129.0 million in 2024, then plummeted by 214.73% to -$148.0 million in 2025, then skyrocketed by 243.92% to $213.0 million in 2026.
  • Business Quant data shows EBT for OGN at $213.0 million in Q1 2026, -$148.0 million in Q4 2025, and $243.0 million in Q3 2025.